1271 Stock Overview
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
SunWay Biotech Co., LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$119.50 |
| 52 Week High | NT$145.50 |
| 52 Week Low | NT$47.30 |
| Beta | -0.047 |
| 1 Month Change | -0.42% |
| 3 Month Change | 3.91% |
| 1 Year Change | 141.66% |
| 3 Year Change | 97.52% |
| 5 Year Change | n/a |
| Change since IPO | 69.99% |
Recent News & Updates
Shareholder Returns
| 1271 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 3.0% | -1.5% | -0.6% |
| 1Y | 141.7% | 8.8% | 29.2% |
Return vs Industry: 1271 exceeded the TW Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: 1271 exceeded the TW Market which returned 25.9% over the past year.
Price Volatility
| 1271 volatility | |
|---|---|
| 1271 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 1271 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1271's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | n/a | sunway.cc |
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business. The company researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp.
SunWay Biotech Co., LTD. Fundamentals Summary
| 1271 fundamental statistics | |
|---|---|
| Market cap | NT$7.10b |
| Earnings (TTM) | NT$94.60m |
| Revenue (TTM) | NT$322.17m |
75.0x
P/E Ratio22.0x
P/S RatioIs 1271 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1271 income statement (TTM) | |
|---|---|
| Revenue | NT$322.17m |
| Cost of Revenue | NT$89.23m |
| Gross Profit | NT$232.93m |
| Other Expenses | NT$138.33m |
| Earnings | NT$94.60m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.59 |
| Gross Margin | 72.30% |
| Net Profit Margin | 29.36% |
| Debt/Equity Ratio | 0% |
How did 1271 perform over the long term?
See historical performance and comparison